Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

[1]  K. Hess,et al.  Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Symmans,et al.  Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Han Wook Park,et al.  Hybrid Fc‐fused interleukin‐7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy , 2020, Clinical & translational immunology.

[4]  Se-Hwan Yang,et al.  hIL‐7‐hyFc, A Long‐Acting IL‐7, Increased Absolute Lymphocyte Count in Healthy Subjects , 2020, Clinical and translational science.

[5]  E. Winer,et al.  TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Astrid Gall,et al.  Ensembl 2020 , 2019, Nucleic Acids Res..

[7]  T. Creasy,et al.  The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort , 2019, Journal of Translational Medicine.

[8]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[9]  M. Minden,et al.  Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia , 2019, Science Translational Medicine.

[10]  D. Berry,et al.  CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). , 2019, Journal of Clinical Oncology.

[11]  A. Godwin,et al.  Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320). , 2019, Journal of Clinical Oncology.

[12]  Jing Wang,et al.  WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs , 2019, Nucleic Acids Res..

[13]  Ryan L. Collins,et al.  Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes , 2019, bioRxiv.

[14]  M. Rezai,et al.  Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[16]  Obi L. Griffith,et al.  Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples , 2018, Genetics in Medicine.

[17]  C. Perou,et al.  Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel , 2018, Clinical Cancer Research.

[18]  N. Harbeck,et al.  Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results , 2018, Journal of the National Cancer Institute.

[19]  D. Groheux,et al.  Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  W. Symmans,et al.  Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[21]  P. Fasching,et al.  Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial , 2017, JAMA oncology.

[22]  Kate Voss,et al.  Full-stack genomics pipelining with GATK4 + WDL + Cromwell , 2017 .

[23]  Dumitru Brinza,et al.  Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy , 2017, npj Breast Cancer.

[24]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[25]  Mei Liu,et al.  Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Giovanni Martinelli,et al.  Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data , 2016, BMC Bioinformatics.

[27]  A. Vincent-Salomon,et al.  Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. , 2016, Clinical chemistry.

[28]  C. Perou,et al.  Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts , 2016, Clinical Cancer Research.

[29]  Mahdi Rezai,et al.  Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival , 2016, Journal of chemotherapy.

[30]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[31]  D. Berry,et al.  Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance) , 2016 .

[32]  Gonçalo R. Abecasis,et al.  Unified representation of genetic variants , 2015, Bioinform..

[33]  Obi L. Griffith,et al.  Genome Modeling System: A Knowledge Management Platform for Genomics , 2015, PLoS Comput. Biol..

[34]  C. Geyer,et al.  Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer , 2015, Annals of Surgical Oncology.

[35]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[37]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[38]  R. Kimmig,et al.  Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response , 2014, Chemotherapy.

[39]  David E Larson,et al.  Using VarScan 2 for Germline Variant Calling and Somatic Mutation Detection , 2013, Current protocols in bioinformatics.

[40]  M. Rezai,et al.  Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[42]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[43]  J. Lubiński,et al.  Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer , 2012, Breast Cancer Research.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[45]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[47]  V. Heinemann,et al.  Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005 , 2011, Anti-cancer drugs.

[48]  A. Soran,et al.  Molecular Class as a Predictor of Locoregional and Distant Recurrence in the Neoadjuvant Setting for Breast Cancer , 2011, Oncology.

[49]  P. Tan,et al.  Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy , 2011, Breast Cancer Research.

[50]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[51]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[52]  J. Kładny,et al.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2009, Breast Cancer Research and Treatment.

[53]  Jeff Myers,et al.  Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. , 2009, Clinical breast cancer.

[54]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[56]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[60]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[61]  P. Liu,et al.  Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[62]  M. Lippman,et al.  Breast Cancer Research and Treatment , 2004, Breast Cancer Research and Treatment.

[63]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .